Blood Testing Market

A blood test is a lab analysis of things that may be found in blood. The blood tests to keep track of how well are managing a condition such as diabetes or high cholesterol. This also have them for routine checkups or when are ill. Blood tests are very common. Furthermore, blood tests can be used for many different things, including to check cholesterol and blood glucose levels. These helps monitor risk of heart and circulatory diseases and diabetes, or how condition is being managed.

Blood Testing Market Drivers:

• Increasing burden of chronic and infectious disease

The burden of chronic diseases is rapidly increasing worldwide. It has been calculated that, in 2001, chronic diseases contributed approximately 60% of the 56.5 million total reported deaths in the world and approximately 46% of the global burden of disease. Moreover, the growing incidence of chronic diseases such as diabetes, cardiovascular diseases, and cancer has led to a rising demand for blood tests for early detection, monitoring, and management.

Opportunities:

• Technological advancements in blood testing devices

Increasing technological advancements in blood testing various devices such as rapid diagnostic test kit. blood pathogens like hiv and malaria, detected in the blood instantly through a rapid diagnostic test kit, microsampling technology, glucose meter, blood chemistry analyzer, complete blood count test. Furthermore, medical technology companies have been making news headlines by promising improved blood tests that are not only precise, but also nearly pain-free since they require only a single drop of blood compared to other current options.

Restraints:

• High Cost of blood testing devices

The cost of blood tests can include the labor and expertise of healthcare professionals who collect and analyze the samples, the cost of materials and reagents used in the testing process, as well as the overhead costs of operating and maintaining a medical laboratory. Furthermore, blood tests require specialized equipment and supplies, such as needles, collection tubes, and reagents. These items can be expensive to manufacture and maintain. This is expected to hamper the growth of the global market.

Segment Overview

• By Test Type

Based on test type, the global blood testing market is divided into glucose testing, A1C testing, direct LDL testing, lipid panel testing, prostate-specific antigen testing, COVID-19 testing, BUN testing, vitamin D testing, others. The glucose testing segment dominated the market in 2023 and is expected to dominating during the blood testing market in forecast period, due high penetration of blood test.

Rising diabetes prevalence and various data show that this trend will likely continue in the future. Furthermore, the International Diabetes Federation reported in December 2021 that around 537 million persons aged 20 to 79 years had diabetes in 2021. Furthermore, advancement in glucometer technological such as bluetooth capabilities and wireless connectivity, improve the adoption of these products. Some examples of smart glucose monitoring products include Dario Health Smart Meter, iHealth Align, iHealth Smart, and Glooko.

• By End Use

Based on end use, the global blood testing market is segmented hospitals, clinic, diagnostic centers. The hospital segment dominated the blood testing market in 2023, owing to growing number of hospital admissions and longer duration of patient stay.

Increasing technological advancement and availability of a broad range of blood test, hospitals offer access to more accurate and efficient diagnostic tools. Moreover, high adoption rate of blood testing services in hospital for facilitating early detection, personalized treatment plans and enhanced patient outcomes.

Blood Testing Market Overview by Region

North America dominated the blood testing market in 2023. The attributed to the strategic measures launched by government authorities and important actors to encourage plasma donations in the region. Blood donation centers across the country are working to improve the collection of plasma from disease-free patients.

Regional expansion is being driven by a variety of causes, including the introduction of new government initiatives, advancements in healthcare infrastructure, and technology advances. Furthermore, regulatory authorities, such as the FDA and the Federal Trade Commission, play an important role in regulating diagnostic tests. In the US, the adoption of Clinical Laboratory Improvement Amendments (CLIA) is expected to boost the utilization of testing.

Blood Testing Competitive Landscape

In the global blood testing market, a few major players exert significant market dominance and have established a strong regional presence. These leading companies remain committed to continuous research and development endeavors and actively engage in strategic growth initiatives, including product development, launches, joint ventures, and partnerships. By pursuing these strategies, these companies aim to strengthen their market position, expand their customer base, and capture a substantial share of the market.

Blood Testing Market Leading Companies

• Abbott Laboratories

• Bio-Rad Laboratories Inc.

• Roche Diagnostics

• Quest Diagnostics

• Danaher Corporation

• Becton, Dickinson and Company (BD)

• bioMé,rieux SA

• Thermo Fisher Scientific

• Siemens Healthineers

• Novartis Diagnostics

Blood Testing Recent Developments

• In March 2023, TruDiagnostic, a health data organization, has forged a strategic alliance with NADMED, a Finnish company renowned for its expertise in nicotinamide adenine dinucleotide diagnostics. Together, they are set to unveil a cutting-edge diagnostic test kit named Q-NADMED, designed to facilitate the precise measurement of NAD+ and NADH levels in blood samples.

• In February 2023, Thermo Fisher Scientific Inc. (US) has recently completed the acquisition of TIB Molbiol (Germany), a move aimed at enhancing its PCR test offerings by incorporating an extensive array of assays designed for infectious diseases. This strategic acquisition enables the company to broaden its portfolio, particularly in the field of digital PCR, a cutting-edge technology renowned for its effectiveness in detecting and quantifying rare mutations and target sequences.

• In September 2021, Roche Diagnostics, headquartered in Switzerland, has successfully acquired the TIB Molbiol Group based in Germany. This strategic acquisition is set to bolster Roche',s extensive molecular diagnostics offerings by incorporating a diverse array of assays designed for infectious diseases, including the identification of SARS-CoV-2 variants.